stoxline Quote Chart Rank Option Currency Glossary
Scholar Rock Holding Corporation (SRRK)
13.85  -0.1 (-0.72%)    04-19 16:00
Open: 13.94
High: 14.2
Volume: 689,578
Pre. Close: 13.95
Low: 13.18
Market Cap: 1,078(M)
Technical analysis
2024-04-19 5:12:29 PM
Short term     
Mid term     
Targets 6-month :  18.63 1-year :  20.9
Resists First :  15.95 Second :  17.89
Pivot price 14.42
Supports First :  12.81 Second :  10.65
MAs MA(5) :  13.76 MA(20) :  14.84
MA(100) :  15.82 MA(250) :  10.96
MACD MACD :  -0.6 Signal :  -0.5
%K %D K(14,3) :  15.3 D(3) :  14.4
RSI RSI(14): 43.6
52-week High :  21.17 Low :  5.55
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SRRK ] has closed above bottom band by 33.8%. Bollinger Bands are 14.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 14.23 - 14.3 14.3 - 14.36
Low: 13 - 13.09 13.09 - 13.16
Close: 13.72 - 13.86 13.86 - 13.98
Company Description

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 16 Apr 2024
Scholar Rock (NASDAQ:SRRK) Stock Price Up 2.9% - MarketBeat

Mon, 15 Apr 2024
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer - The Globe and Mail

Thu, 28 Mar 2024
Scholar Rock Holding Corp (SRRK) is down -1.98% in a Week, Should You Buy? - InvestorsObserver

Wed, 27 Mar 2024
Technical Analysis of Scholar Rock Holding Corporation - TradingView

Wed, 20 Mar 2024
Scholar Rock Holding Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily

Tue, 19 Mar 2024
SRRK Stock Earnings: Scholar Rock Holding Misses EPS for Q4 2023 - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 78 (M)
Shares Float 48 (M)
Held by Insiders 2.2 (%)
Held by Institutions 106.9 (%)
Shares Short 12,520 (K)
Shares Short P.Month 11,170 (K)
Stock Financials
EPS -2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.96
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -32 %
Return on Equity (ttm) -68.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.17
Qtrly Earnings Growth 0 %
Operating Cash Flow -145 (M)
Levered Free Cash Flow -81 (M)
Stock Valuations
PE Ratio -6.96
PEG Ratio 0
Price to Book value 4.67
Price to Sales 0
Price to Cash Flow -7.43
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android